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The Science of Aging 
 
1. General i t ies 
	
Why does aging occur? This is a common and tough question 
that arises as time goes by. Aging constitutes one of the biggest 
concerns for the human being and to ask why do we age is to enter the 
field of evolutionary biology, which is crucial to understand health and 
disease [1]. Nowadays, researchers’ challenge focus on explaining the 
reasons of aging rather than the obvious drawbacks of the natural 
process. 
 
Aging is commonly characterized as a progressive and 
generalized impairment of function, resulting in an increased 
vulnerability to genetic and environmental factors [2-4]. Getting older is 
in fact, an enigmatic biological process highly medically relevant, since 
despite considering increased longevity a remarkable achievement for 
the humankind, aging is the major risk factor for the development of 
chronic diseases and represents an extraordinary financial burden on 
the health care systems [5], therefore constituting a sanitary and a 
socioeconomic concern. It is estimated that in twelve years, a great 
percentage of the population will be aged 65 or older [6] [Figure 1], 
and according to the World Health Organization (WHO), between 2015 
and 2050, the proportion of the world’s population over 60 years old, will 
nearly double, from 900 millions to 2000 million people, which will 
represent an increase of 10% [7]. 
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Figure 1. Population becomes older. People aged 65 or older (light bars) and 85 
years old or older (dark bars) in the United States from 1900 through 2030. Data and 
image credit: US Census Bureau data with projections for 2030 and, Lakkata EG, Levy D. 
Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises, part 
I: aging arteries: a "set up" for vascular disease. Circulation. 2003, 107: 139-146. 
	
The aging process is linked to an accumulation of mutations 
and genomic instability resulting in a progressive functional and 
structural decline in multiple organs. Then, far from being considered an 
illness in itself, aging is the greatest risk factor for the onset of chronic 
age-related diseases including cardiovascular disease, cancer, 
diabetes, neurodegenerative diseases, and higher tendency to infection 
[8].  
 
As aforementioned, accumulation of DNA damage is a common 
feature of aging cells that generally occurs during DNA replication step, 
where most cells undergo division in order to maintain cell population in 
tissues and thus, a proper function of the organs. It is crucial for cells to 
accurately replicate their DNA, since during copying DNA strands, 
mistakes may occur and such inaccuracy may introduce alterations in 
cellular function. Although cells have evolved a complex network of 
DNA-repair mechanisms that are collectively capable to deal with most 
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of the DNA damage affecting the nuclear DNA, these mechanisms may 
not be perfect and mistakes can sleep through. It has been shown in 
many studies that such mistakes in DNA accumulate in cells with age 
[9-12]. Thus, it is vital to underline that the mutations introduced during 
DNA replication that remain after unsuccessful repair mechanisms are 
irreversible, causing genetic damage accumulation and increasing 
genomic instability during lifetime. 
	
1.1. Cellular Aging and the Senescence-Associated 
Secretory Phenotype 
	
Cellular or replicative senescence was first proposed in 1961 
[13, 14]. Since that time, it has been shown in various studies to be a 
significant tumor restricting mechanism that halts proliferation in 
response to damage that occurs during replication [15-19], enabling the 
organism to antagonize the potentially detrimental effects of 
uncontrolled growth. Morphologically, senescence cells acquire a 
characteristic morphological type consisting on cellular enlargement and 
flattering. However, senescent cells can also acquire a secretory 
phenotype, which is damaging and irreversible, termed senescence-
associated secretory phenotype (SASP). This deleterious phenotype 
involves secretion of interleukins and growth factors, degradative 
enzymes like metalloproteases, and insoluble proteins [15, 20] that may 
alter tissue homeostasis and affect neighbouring cells promoting tumour 
progression [21-23].  
 
The senescent phenotype has been widely associated with 
driving organismal aging. The SASP is a response to genomic damage 
that stimulates tissue repair by attracting immune cells and 
subsequently, induce local inflammation. What it is very interesting, is 
the belief that SASP also has certain beneficial effects by secreting 
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several chemokines and cytokines that activate immune cells to 
specifically target and clear senescent cells from tissues [24, 25]. 
Besides, some SASP factors are also involved in tumour suppressive 
growth arrest of cells [26, 27]. However, aging determines the change 
from a temporal programmed process to a continual stochastic 
response, since there is an evident age-related decline in the immune 
system and in the efficiency of senescence-cell clearance. 
 
SASP factors, because of cellular senescence, are involved in 
several chronic processes [Figure 2]. Recent research performed in 
murine models report that the onset of chronic diseases is delayed 
when senescent cells are genetically removed [28]. Byun et al., [29] 
definitively proposed the connection between cell senescence and age-
associated diseases where they postulate that senescent cells have the 
ability to modulate young cells by releasing inflammatory SASP factors, 
such as IL-1. The SASP enables the onset of different pathologies by 
promoting a proinflammatory state. For instance, obesity, type 2 
diabetes mellitus, hypertension and atherosclerosis, among other 
cardiovascular risk factors that compromise metabolism, are associated 
with cellular senescence and SASP [30].  
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Figure 2. I l lustrative representation of t issues and their related diseases as 
we age. Both cellular aging and senescence-associated secretory phenotype (SASP) are 
involved in the onset and development of inflammaging or aged-related pathologies linked 
to inflammation. Abbreviations: AD- Alzheimer’s disease; PD- Parkinson’s disease; MD- 
Macular degeneration; CVD- Cardiovascular disease; COPD- Chronic obstructive 
pulmonary disease; CKD- Chronic kidney disease.	
 
1.2. Aging theories: Evolutionary and molecular basis 
outlook 
 
The complexity of the aging process can be elucidated by many 
theories. However, there is not yet an exact mechanism to explain how 
this phenomenon occurs. In 1882, August Weismann proposed the 
wear and tear theory. The basis of this theory, consist on comparing 
organisms to machines, and holds that cells, like components of an 
aging car, burn out with time from repeated use and accumulate 
damage due to an excessive consumption of fat, sugar or, exposure to 
UV radiation, finally leading to a functional decline in organs [31]. 
However, this theory does not take into account that cells are able to 
repair from DNA damage. Consequently, the stochastic theory arose as 
a byproduct of this hypothesis suggesting that aging is due to an 
inefficiency of cell mechanisms to repair damage caused by 
environmental stress, UV radiation, or infections [32]. 
 
	
General introduction & thesis outl ine 	
	18	
Theories of aging regarding evolution propose the idea that 
certain genes involved in longevity are also involved in the homeostasis 
of somatic cells, and very prone to mutations during aging. 
 
Two of the main evolutionary theories of aging are possibly 
Medawar’s mutation and accumulation theory (Medawar 1952) [33] and 
the antagonistic pleiotropy theory (Wiliams 1957) [34]. Both theories 
hold a concept based on the same principle: As we age, natural 
selection is not effective enough to eliminate deleterious genetic 
variations, whose effects will be shown in late periods in life.  
 
In this context, Medawar proposes that genomic variations 
associated with certain diseases, or with physiological decline in aging, 
tend to accumulate and take place once reproductive years are gone. 
On the other hand, Williams postulates the antagonistic pleiotropy 
theory, adding an adaptive aspect to the first proposed hypothesis: 
genetic variations linked to age related diseases may be conserved in 
the population if these variations confer an adaptive advantage during 
reproductive years, either protecting against an illness, or increasing 
reproductive possibilities. The mutation accumulation and the 
antagonistic pleiotropic theories provide together, the basis for much of 
the ongoing thinking about the evolutionary genetics in the field of aging 
[35, 36].  
 
At a molecular level, evidence suggests that most of the main 
mechanisms involving damage are linked to macromolecules. The main 
theories that explain how aging occurs are illustrated here below: 
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1.2.1. Somatic DNA damage and Mutation Theory 
 
Since 1994, it is believed that there is a general and solid 
relationship between longevity and DNA repair [37], suggesting that the 
capacity for DNA repair is an important aspect to determine the rate of 
aging at cellular and molecular levels. Studies on the enzyme poly 
(ADP-ribose) polymerase-1, also termed PARP-1, can clarify this fact 
since this molecule is a key player in the immediate cellular response to 
stress induced DNA damage [38]. Higher expression of PARP-1 activity 
level is associated with longer life spans between species and within 
species [39, 40].  
	
1.2.2. Mitochondrial Decline Theory and Oxidative Stress 
Theory  
 
Apart from nuclear DNA, certain mutations can also cause 
damage in mitochondrial DNA (mtDNA) as we age [41]. It has been 
reported that there is a link between molecular stress and aging caused 
by the accumulation of mtDNA mutations. Cytochrome C oxidase (COX) 
deficient cells are directly associated with mtDNA mutations in human 
muscle [42, 43], brain [44, 45] and gut [46].  
 
One of the best-known and most conventional approaches to 
date is the mitochondrial free radical theory of aging or the nowadays-
termed oxidative stress theory (OST) [47]. Oxidative stress hypothesis 
interprets aging at a molecular level, explaining that aging occurs due to 
an imbalance between the production of reactive oxygen species (ROS) 
and the capacity of the biological system to repair the outcoming 
damage, resulting in the failure to maintain the mitochondrial integrity 
and DNA repair. ROS molecules include superoxide (O2•-), hydroxyl 
radical (OH•), hydroperoxyl radical (HO2•), nitric oxide (NO•), nitrogen 
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dioxide (NO2•), and peroxyl (ROO•), produced either as by-products 
during the mitochondrial electron transport of aerobic respiration or by 
oxidoreductase enzymes.  
 
1.2.3. Telomere Shortening Theory  
 
Telomeres are repeated nucleotides sequences that are 
believed to protect the ends of linear eukaryotic chromosomes from 
fusing other DNA strands. During cell division, telomeres tend to get 
progressively shorter, losing a little bit of their length [48]. Since 
telomerase, which is a specialized DNA polymerase that could replicate 
telomeres, is only present in germ cells (testis and ovary) and is absent 
in normal mammalian somatic cells, telomeres become too short to 
replicate showing a decline in cellular capacity division with age. 
 
 Eventually, the cell will arrest the cycle and enter cellular 
senescence. Some suggest that in dividing somatic cells, after a fixed 
number of divisions, telomeres protect us against uncontrolled cell 
replication as happens in cancer, but causing aging as a side effect 
[49]. It has been reported that telomeres are particularly susceptible to 
accumulation of DNA damage with age, and this damage is restricted to 
be repaired because of a multiprotein complex termed shelterin that 
binds to the telomeres and prevents the access of DNA repairing 
proteins to the telomeres. Therefore, DNA damage at telomerases is 
persistent, inducing cellular senescence [50]. 
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1.2.4. Altered Proteins and Waste Accumulation Theory 
 
Protein turnover is vital to maintain cell function by removing 
damaged or unnecessary proteins. Chaperones help sequestering and 
restoring denatured proteins and proteasomes. Proteasomes are 
involved in recognizing and selectively degrade damaged and 
ubiquitinated proteins. When there is not a correct recycling process 
and damaged proteins accumulate with time due to impairment in 
protein turnover, there is a great tendency to develop a wide range of 
age-related pathologies, including cataract, Alzheimer’s, and 
Parkinson’s disease. There is evidence suggesting that exits a 
functional decline in the activities of both, chaperones [51] and 
proteasomes [52] as we age. These declines are translated into a more 
general and serious failure caused by waste accumulation [53].  
 
Until date, several aging mechanisms are widely 
acknowledged. However, they are not fully satisfactory. Most research 
is focused on unique mechanisms of theories that indicate that 
hypothetical molecular and cellular lesions do occur as we age, but 
there is no data evidencing the theory itself to be sufficient to clarify 
age-related diseases. Much of the recent proliferation of aging theories 
arose from an inquisitiveness to see the different hypothesis competing 
to better explain how aging occurs. Therefore, recent initiatives state 
that these theories may interact with each other in a more sophisticated 
manner, like a network of aging theories considering the contribution of 
various mechanisms together and allowing the interaction among 
different processes [54].  
 
For instance, it is well known that a gradual accumulation of 
mutations in mtDNA over years, may lead to a steady increase in both 
ROS production, and energy consumption. This initiates the process, 
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but what ultimately damages the cell is the collapse generated in the 
homeostatic mechanism. By understanding these connections, it may 
be possible to mediate against cell deterioration and promote 
successful aging [3]. 
 
Advancing age is the major risk factor for the development of 
many chronic diseases, and more specifically, for cardiovascular 
disease (CVD), which has become a widespread global fact no longer 
considered a disease restricted to western-type societies. 
Cardiovascular events represent more than 30% of all deaths 
worldwide, including hypertension, myocardial infarction, and stroke 
[55]. Many of these events occur prematurely before the age of 60, and 
according to the World Health Organisation (WHO), the majority of them 
could have been prevented [56]. 
	
	2. Aging and Calorie Restr ict ion 
 
Cardiovascular disease (CVD) is traditionally believed to be due 
to an accumulation of cholesterol and fatty acids in the heart and 
vessels, triggering an inflammatory response and ROS production, and 
therefore compromising tissue function. A different point of view arose in 
1935, when McCay et al., reported that dietary or caloric restriction 
(CR), a 20 to 40% reduction in calorie intake, definitely extended 
lifespan in rats [57]. Here emerged a new concept in the aging field 
stating that a high-calorie diet without exercise may supress the 
expression of genes involved in longevity, since it has been reported 
that CR reduces insulin-like growth factor-1 (IGF-1) levels in yeast and 
mammals, and prevents the onset and development of age-related 
cardiovascular events [58-60]. For example, CR delays the 
development of atherosclerotic lesions in mice [61], improves LV 
diastolic function of the aging heart [62, 63] and diminishes arterial 
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stiffness [59, 64]. Thus, long-term CR has a potent effect in preventing 
and delaying severe cardiomyopathy in various animal models. 
	
Interestingly, some exceptions and adverse results in certain 
inbred and outbred strains of mice have been reported [65-67], 
suggesting that CR on survival is not universal and may affect health 
and lifespan depending on the strain and sex [68]. However, data from 
human studies indicate that populations like Okinawans, who intake a 
slightly reduced calorie diet (1785 kcal/d approximately), show lower 
rates of coronary heart disease and higher frequency of centenarians. 
According to this fact, some studies report that individuals under long-
term calorie restriction are less prone to develop cardiovascular events 
[69].    
CR plays a role in the modulation of longevity pathways, since 
CR regulates four key genes involved in aging: AMP-activated protein 
kinase (AMPK), insulin/insulin-like growth factor 1 (IGF-1), nicotinamide 
adenine dinucleotide (NAD)+-dependent deacetylases (sirtuins), and the 
mammalian target of rapamycin (mTOR). Consistent with this, there is 
reasonable interest in finding pharmacological agents that mimics CR. 
Resveratrol [70], rapamycin [71] and more recently, metformin [72, 73] 
are some examples of the main compounds that mimic CR and prevent 
pathology onset by regulating genes involved in longevity pathways 
[Figure 3]. Some examples of a variety of model organisms are: the 
yeast Saccharomyces cerevisiae, the nematode Caenorhabditis 
elegans, and the fly Drosophila melanogaster, which have served to 
identify a number of longevity genes, their related pathways and 
therefore, their connection with aging and more specifically, with their 
roles in cardiovascular aging.  
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Figure 3: Calorie restr ict ion promotes improved longevity. By modulating certain 
factors involved in the longevity network, caloric restriction may enhance not only lifespan, 
but also health-span. Black arrows indicate activation and red arrows indicate inhibition. 
Abbreviations: CR- Caloric restriction, NAD- Nicotinamide adenine dinucleotide, AMPK- 
Adenosine monophosphate protein kinase, mTOR-mammalian target of rapamycin, IGF-1- 
Insulin-like growth factor-1, AKT- Serine/threonine kinase Akt, also designed protein 
kinase b. 	
	
3. Major genes involved in Aging 
	
Four main important genes including AMPK, IGF-1, Sirtuins, 
and TOR govern longevity pathways.  
	
3.1. AMP-activated protein kinase (AMPK) 
	
AMPK is composed of two α, two β and three γ subunits [74], 
which are regulated by AMP binding. AMPK works as a metabolic 
sensor regulating the AMP: ATP ratio and is involved in glucose and 
lipid metabolism. In heart tissue, AMPK activity plays a role in fatty acid 
and glucose uptake and glycolysis, whereas in liver, is involved in fatty 
acid and cholesterol synthesis and glucogenesis [72, 75]. It modulates 
autophagy and mitochondrial function [76] by triggering the destruction 
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of defective mitochondria through a mitochondrial-specific process of 
autophagy termed mitophagy and through activation of mitochondrial 
biogenesis. With concern to longevity network [Figure 4], AMPK 
modulates some important pathways, including IGF-1 pathway through 
the extracellular signal-regulated kinase (ERK1/2) cascade [77], 
modulates the abundance of NAD and nicotinamide 
phosphoribosyltransferase (Nampt) [78, 79], and inhibits mTOR through 
direct phosphorylation of the TSC1/2 complex [6]. AMPK is essential to 
maintain cardio-metabolic homeostasis. This kinase has shown to be 
cardioprotective during ischemia. According to some research, mouse 
models lacking AMPK functionality, had exarcebated myocardial 
infarction [80]. Activation of AMPK by metformin reduced overload- 
induced cardiac hypertrophy [81] and thirdly, mutations in the regulatory 
γ 2 subunit led to a familial syndrome of hypertrophic cardiomyopathy 
[82]. Considering that AMPK is a master regulator of energy balance 
and metabolism, its modulation has shown to be an interesting target to 
regulate metabolic pathways. Interestingly, it has been recently reported 
that nutraceutical compounds, including resveratrol, hydroxytyrosol or 
some flavonols among others, have AMPK-mediated therapeutic effects 
on diabetes mellitus and CVD [74], which gives a natural approach to 
AMPK pathway activation.  
	
3.2. Insulin/ insul in- l ike growth factor 1 (IGF-1) 
	
One of the first genes to be characterized as a longevity gene 
was IGF- 1. The loss of IGF- 1 in the nematode C elegans showed to 
increase lifespan [83] and, decades of studies pointed to reduced IGF-1 
signaling as a strategy to prevent cells from aging and pathology onset. 
These findings led to identify all the genes that could be involved in IGF-
1 pathway to modulate lifespan. In the longevity network [Figure 4], 
IGF-1 signaling modulates mTOR through Akt activity [84]. At heart 
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level, overexpression of IGF-1 showed to protect against myocardial cell 
death after infarction and reduced hypertrophy and diabetic 
cardiomyopathy [85, 86]. Paradoxically, other studies report that 
overexpression of IGF-1 led to cardiac hypertrophy and heart failure 
[87]. These variations may be due to existing different isoforms of IGF-
1. 
 
3.3. Sirtuins (Sir2) 
 
The sirtuins are a family of proteins that function as 
nicotinamide adenine dinucleotide (NAD)-dependent deacetylases and 
ADP-ribosyltrasnferases. In mammals, seven sirtuin family members 
exist, and have different localizations in the cell. For example, Sirt3, 
Sirt4, and Sirt5 are found exclusively within the mitochondria. However, 
Sirt1 and Sirt6 are generally localized in the nucleus. Sirtuins regulate 
several cellular functions including DNA repair and cell cycle among 
others [88]. The role of sirtuins was first observed in a model of 
replicative lifespan in yeast, which measured the number of times a 
yeast mother cell produced a daughter cell before going senescent. Up 
until now, numerous studies have kept sirtuins as a key component of 
the longevity network [Figure 4], having shown to modulate aging from 
yeast to mammals [89-93]. For instance, Sirt1 regulates AMPK pathway 
through deacetylation of liver kinase B1 (LKB1) [94], regulates IGF-1 
through modulation of UCP2 expression [95], and interacts with TSC 1/ 
2 by inhibiting mTOR activity [96, 97]. Within cardiovascular aging and 
disease, some studies report that Sirt1 knock out (KO) mice have 
greater injury in response to ischemia reperfusion, which is attenuated 
in Sirt1 transgenic mice [98]. Cardiac-specific Sirt1-overexpressing mice 
showed delayed age-related cardiomyopathies and resistance to 
oxidative stress and apoptosis. Interestingly, when extensive Sirt1 
overexpression occurred (around 20 fold), resulted in undesirable 
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effects including oxidative stress, apoptosis and cardiomyopathy [99, 
100]. Mitochondria-localized Sirt3 showed to prevent age-dependent 
cardiac dysfunctions in KO mice [101, 102]. Mice deficient in Sirt6 
developed a drastic premature aging phenotype, characterized by a 
failure to grow healthily, intestinal sloughing, hypoglycaemia and 
remarkable shortened lifespan [90]. Finally, Sirt7 seemed to protect 
mice from cardiac hypertrophy and inflammatory cardiomyopathy [93]. 
Despite the fact that research reports that sirtuins seem to have many 
beneficial effects on cardiovascular health, the molecular mechanisms 
by which sirtuins regulate the heart is not yet fully understood. 
	
3.4. Mammalian Target of Rapamycin (mTOR) 
	
The serine- threonine protein kinase mammalian target of 
rapamycin (mTOR) is a master regulator of cell growth and metabolism. 
Deregulation of mTOR pathway may lead to human diseases, such as 
cancer [103], diabetes, obesity and neurological and genetic alterations  
[104]. Deletion of TOR or its inhibition through treatmeant with 
rapamycin has been observed to extend lifespan in yeast, flies, worms 
and mammals [71, 105- 107]. Inhibition of mTOR signalling in the heart 
with rapamycin restrains cardiac hypertrophy caused by pressure 
overload [108, 109], probably through mTOR control of protein 
translation and cell size blockage. Moreover, the PI3K/AKT/mTOR 
pathway in which is involved plays a main role in a number of signalling 
pathways, placing this pathway as a crucial mediator of cardiovascular 
metabolism and aging. Regarding the longevity network [Figure 4], 
mTOR acts as an effector of upstream sirtuin/AMPK/IGF-1 activity and 
its inhibition, either through rapamycin or nutrient-poor conditions 
activates autophagy, which promotes cardiovascular health by 
destructing defective macromolecules [110]. 
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Figure 4: Longevity network organization. Major genes involved in longevity 
network system concerning aging and lifespan. Abbreviations: LM- Lipid metabolism; MF- 
Mitochondrial function; A- Autophagy; SR- Stress resistance; PS- Protein synthesis; M- 
Metabolism. Green and black arrows indicate activation of a physiological function or a 
concrete gene, respectively. Red arrows indicate their inhibition.	
	
In a recent study, López- Otín el al., have explained aging 
decline as a result of a number of different events occurring in the 
organism that can be described and classified into several “hallmarks” 
[50]. Among these hallmarks of aging are included: loss of proteostasis, 
epigenetic alterations, telomere shortening, DNA damage or genomic 
instability, deregulated nutrient sensing, accumulation of dysfunctional 
organelles, cellular senescence, stem cell exhaustion and altered 
intracellular communication. Furthermore, the self-degradative process 
of autophagy, which is crucial to maintain cardiac homeostasis and 
confers the cells the ability to adapt to unfavourable environments and 
stress [Figure 5], is unquestionably a main contributor to progressive 
decline in aging and loss of cell quality control. 
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Figure 5: Correct autophagy is essential to promote healthy aging. 
Documented hallmarks of aging by López- Otín et al., including inaccurate autophagy as a 
marker involved in aging decline. 
 
4.  Autophagy and aging 
	
Autophagy is a great cellular quality control pathway, 
responsible for selectively removing dysfunctional organelles and 
protein aggregates to promote cell survival. It is generally accepted that 
aging is characterized by a reduction in autophagy activity [111-116], 
believing that insufficient autophagy is a major contributor to aging 
decline.  
	
Autophagy is a tightly regulated degradation pathway, whose 
activity is regulated by the coordination of both intracellular and 
extracellular signals, being AMPK, mTOR and complex III PI3K central 
regulators of the process. mTOR is involved in cell growth and 
metabolism. When it is activated, autophagy gets inhibited. For 
example, in a situation of nutrient enrichment environment, the 
PI3K/AKT signaling pathway, specifically inhibits autophagy through 
activation of mTORC1 complex [115-117]. Contrarily, under nutrient 
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limiting conditions autophagy becomes active by AMPK, via various 
mechanisms. For example, AMPK activates autophagy by inhibiting 
mTORC1 [Figure 4] through phosphorylation of RAPTOR [118] or by 
activating TSC1/2 [119]. AMPK is also involved in autophagy activation 
through Unc-51 like kinase-1 (ULK1) [120] and Beclin-1 complex [121]. 
 
Autophagy consists therefore, on several sequential steps. 
Autophagy-related proteins (ATG) regulate the biogenesis of the 
autophagosome. The complex in charge of the initiation of the 
phagophore formation is promoted by the activation of the core proteins 
Beclin1-Vps34-Vps15 through ULK1 [122]. Then, the elongation of the 
phagophore into an autophagosome involves two ubiquitin-like 
conjugation systems, Atg5-Atg12-Atg16L and microtubule-associated 
protein 1 light chain 3 (LC3) [123]. The resulting conjugated LC3 II is 
then integrated into the membrane and is necessary for pagophore 
elongation and cargo recognition [124]. The phagophore continues 
growing until it closes on itself, absorbing the cargo to be degraded. A 
cargo-loaded autophagosome is formed to fuse with a lysosome and 
originate an autolysosome. Finally, the generated cargo and the inner 
membrane of the autophagosome are degraded by the lysosomal 
hydrolases obtaining basic components to promote cell survival [125]. 
 
At mitochondrial level, also exists a form of autophagy, which 
consists on cleaning dysfunctional mitochondria due to damage or 
stress [126]. This process is termed mitophagy and examples of 
proteins involved in mitophagy include p62/Sqstm1, or PINK/Parkin 
pathway, responsible for marking depolarized mitochondria [127]. 
Premature aging phenotype and reduced lifespan have been associated 
with mice lacking the protein p62/Sqstm1 [128]. This lack may lead to 
accumulation of dysfunctional mitochondria in cardiac tissue, what 
suggests that autophagy plays a vital role in preventing premature 
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aging. 
 
Furthermore, studies have reported that genetic or 
pharmacologic improvements in autophagy should counteract age-
associated decline leading to extended lifespan [129-133], whereas 
inhibiting autophagy might shorten lifespan [134]. For instance, 
pharmacological activation of autophagy using rapamicyn, the mTOR 
inhibitor, promotes longevity in the fly Drosophila melanogaster [135] 
and in aged mice [71, 136]. Likewise, mice with reduced mTOR 
expression have shown longer lifespan [137]. 
 
Manipulation of autophagy also affects cardiac function and 
health. It has been demonstrated that long-term intake of fat inhibits 
autophagic flux in heart in an animal model [138]. CR however, which is 
a potent inducer of autophagy in heart, produces the opposite effect 
[139]. Long-term CR treatment is linked to AMPK activation, and 
preserved contractile function in aged mice [131]. Moreover, 
administration of rapamycin showed to reverse age-related decline in 
cardiac function in mice [140].  
 
Despite the fact that several studies report that autophagy is 
reduced in aged tissues [111-115], studies on autophagy in the aging 
heart are inconsistent. Some report that autophagy is increased; some 
say that it is decreased and in other situations, autophagy remains 
unchanged. On the one hand, it has been reported that aged mice 
hearts show higher levels of Beclin1 and LC3 II/I [141], on the other 
hand, an increase in LC3 II levels was observed in aged tissues, but no 
changes were shown in Beclin1 or p62 levels [142]. Surprisingly, 
another study reports a decrease in LC3 II levels in murine cardiac 
tissue [134]. 
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Gathering all these data, one gets to the conclusion that such 
differences may be due to experimental design or to strain and 
background of mice. What it is clear is that additional research is 
needed to better understand autophagy in cardiac tissue and therefore, 
cardiac aging.  
 
Until date, many theories and biological processes could 
explain aging decline and how it constitutes a major risk factor for 
cardiovascular and cardio-metabolic events. Nevertheless, several 
studies demonstrate that immunological inflammation might be highly 
associated with aging, since the immune system is programmed to 
decline over time [143]. This concept is termed immunosenescence, 
where the innate immunity response is remarkably activated, leading to 
the senescent low-level, chronic inflammatory phenotype known as 
inflammaging.   
	
5. The NLRP3-inf lammasome and inf lammaging 
	
The inflammasomes are intracellular multimeric complexes that 
drive the activation of inflammatory caspases [144]. In particular, 
NLRP3 inflammasome has been involved in the pathogenesis of several 
acquired inflammatory diseases, such as Cryopyrin-associated periodic 
fever syndromes (CAPS) caused by inherited NLRP3 mutations [145]. 
NLRP3-inflammasome is also involved in metabolic-induced 
complications characterized by a low-grade systemic inflammatory state 
triggering an innate immune response to a multitud of endogenous 
metabolic danger patterns inducing sterile inflammation. In that respect, 
NLRP3-inflammasome complex has been described to be activated 
when high-fat, and high-sugar nutrients are consumed, contributing to 
several inflammatory and metabolic disabilities onset [146]. 
Overnutrition and acquired western-type habits are described as major 
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risk factors for cardiovascular and metabolic events onset [147].  
 
Therein, all these metabolic-induced complications and age-
reated diseases share a low-grade systemic inflammatory response that 
triggers NLRP3 activation. In aging field, this typical inflammatory 
condition is termed inflammaging.  
 
The idea of inflammaging was originally introduced in 2000 
[148] by C. Franceschi, referring to a progressive increase of a 
proinflammatory state, a systemic low-grade inflammatory process that 
contributes to the onset and development of chronic diseases and 
degenerative changes as we age. Curiously, age-related inflammation 
in certain organs may lead to a noticeable decline even in the absent of 
any disease. For instance, chronic inflammation is at the same time 
related to aging and also to its associated diseases, including diabetes, 
atherosclerosis, cancer and neurodegenerative diseases. It is generally 
believed that systemic low-grade chronic inflammation potentially 
contributes to incremented age-associated disease prevalence and 
severity [149], since aging is related to an increase in interlukins, such 
as IL-18, IL1β, and IL-6. Furthermore, IL1β and IL18 are particularly 
produced after inflammasome-dependent caspase-1 activation and 
interestingly, the majority of the endogenous signals that have been 
described as inflammasome activators, are known to accumulate as we 
age. 
	
5.1. Structure of NLRP3-inf lammasome  
 
Structurally, inflammasomes consist of an intracellular sensor 
protein, the Nod-like receptor (NLR); the adaptor apoptosis- associated 
speck-like protein containing a caspase recruitment domain (ASC) and, 
the proinflammatory caspase-1 precursor [150]. NLRs are classified 
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according to the domain structure. Generally all NLRs, except for 
NLRP10, contain a leucine-rich repeat (LRR) domain, which is believed 
to provide the critical structural framework for molecular interactions 
[151], and enables the recruitment of caspase-1, either directly through 
CARD-CARD interactions, such as NLRC4 inflammasome, [152] or 
indirectly through a PYRIN domain that is shown to bind to apoptosis-
associated speck-like protein containing a CARD (ASC).  
Apart from the NLR family, non-NLR proteins such as the AIM2-
like receptor (ALR) family can also assemble to conform 
inflammasomes. ALR family contains an HIN200 DNA-binding domain 
instead of an LRR. Therefore upon sensing certain stimuli, either NLR 
or AIM2 can oligomerize to be a caspase-1 activated scaffold. 
Interestingly, NLRs share a similar structure which consist of 
three domains:  
1. NOD or NACHT, a central nucleotide binding 
oligomerization domain. 
2. A C-terminal domain, LRR, which is present in 
all inflammasome members except for NLRP10.  
3. An N-terminal domain of recruitment of effector 
molecules, which determines the classification of the 
different NLRs [Figure 6]. 
NLPR3 is probably the most in depth-studied inflammasome 
due to its gamut of known stimuli activating the complex.  
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Figure 6: Domain key organization and NLRP3-inflammasome classif ication 	
according to i ts domain structure. Inflammasomes are named according to the 
protein forming the scaffold. NLRs proteins are categorized in four subfamilies depending 
on the kind of N-terminal domain: N-terminal domain in NLRP subfamily is PYD.  
	
Despite the fact that Nlrp3 inflammasome is the most 
thoroughly studied NLR, its complex mechanism of activation has 
shown to be even more sophisticated with the discovery of non-
canonical inflammasome activation [153]. Here, the authors show that 
caspase-11 is critical for caspase-1 activation and IL-1β production in 
C57BL/6 Casp11 gene-targeted mice macrophages infected with 
Escherichia coli, Citrobacter rodentium or Vibrio cholerae. 
5.2. Mechanisms of activation of NLRP3-inf lammasome 
Schroder and Tschopp [150] first described the inflammasome 
as a complex of multimeric proteins that assemble in the cytosol when 
pathogenic microorganisms or sterile stressors are present, considering 
this large complex tightly linked to the onset of the inflammatory 
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response, since they act as intracellular innate immune sensors [150]. 
Among all the inflammasomes described until date, the most in depth 
studied is the NLRP3-inflammasome, presumably because of its 
complete range of activators. NLRP3 can be activated in response to 
many different microbial, environmental or metabolic stimuli, which 
conclude in ROS generation, changes in ion flux, or cathepsin B 
emanation into the cytoplasm [154-156] [Figure 7]. 
	
5.2.1. Canonical activation of NLRP3-inf lammasome  
	
Although under physiological conditions NLRP3 remains 
inactive, the complex requires two steps to be fully activated [Figure 
7]. The first signal or priming consists of the activation of nuclear factor 
κB (NF-κB) [157] and the transcription of inflammasome constituents 
[158]. Signal two or triggering is represented by sensing a gamut of 
pathogen-associated molecular patterns (PAMPs) and stress-
associated signals or host-derived damage-associated molecular 
patterns (DAMPs) to trigger NLRP3 oligomerization and final complex 
assembly [158-160]. The inflammasome assemblage concludes with 
the activation of caspase-1, which generates a signaling cascade that 
leads to maturation and pro-inflammatory cytokines (IL-1β and IL-18) 
release.  Active caspase-1 also promotes pyroptosis in an independent 
manner of IL-1β maturation [152, 161]. Pyroptosis is a key defense 
mechanism against microbial infections, which acts blocking 
intracellular pathogens replication and promoting phagocytosis of 
surviving microbes [162]. Interestingly, most of the DAMPs that provoke 
the inflammasome activation such as asbestos, silica [163], certain 
toxins, ATP [164] or uric acid crystals [165] among others, have shown 
to increase during aging [166]. 
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Figure 7: Canonical mechanism of activation of NLRP3-inflammasome. 
Activation of NLRP3-inflammasome requires two different signals: Signal 1 or priming and 
signal 2 or triggering. The fully activation of NLRP3 ends with caspase-1 activation and a 
form of inflammatory cell death termed pyroptosis. Abbreviations: PAMPs-Pathogen-
associated molecular patterns, DAMPs-Damage-associated molecular patterns, TLR-Toll 
like receptor, NF-kb-Nuclear factor kappa beta, CARD-Caspase recruitment domain, and 
ASC-Apoptosis-associated speck-like protein containing a CARD.	
	
5.2.2. Non-canonical activation of NLRP3-inf lammasome 
	
Appart from canonical activation, non-canonical caspase-11-
dependent NLRP3 activation has been described as well [167]. 
Caspase-11 becomes active in response to cytosolic LPS gram-
negative bacteria, including Escherichia coli, Citrobacter rodentium, and 
Vibrio cholerae [153], flagellin-deficient Legionella pneumophila [168], 
and Salmonella typhimurium [169]. Some studies suggest that TLR4-
TRIF-mediated type I interferon dependent production of caspase-11 
[170, 171] is required for non-canonical NLRP3-inflammasome 
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activation [Figure 8]. Once gram-negative pathogenes activate TLR4-
TRIF pathways, nuclear translocation of NF-kb promotes the 
transcription of proinflammatory interleukins IL-1b and IL-18 on the one 
hand, and the transcription of interferon regulatory factors IRF3 and 
IRF7 genes, on the other [172]. Later, the IRF3–IRF7 complex provokes 
the expression of interferon-α/β, which binds to the corresponding 
IFNAR1/IFNAR2 receptor, finally driving to the JAK/STAT pathway  
activation and resultant transcription of caspase-11 gene [172]. 
Moreover, the binding of lipopolysaccharide (LPS) from gram-negative 
bacteria to caspase-11 has demonstrated to induce escaping 
phagosomes that activate caspase-11 [173, 174]. Then, activated 
caspase-11 activates pyroptosis through cleavage of gasdermin D, and 
promotes IL-1β release through activation of the NLRP3-ASC-caspase-
1 pathway [175, 176] [Figure 8]. 
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Figure 8: Non-canonical activation of NLRP3-inflammasome. Gram-negative 
bacteria LPS stimulate TLR4-TRIF pathways. Then, translocation of NF-kb promotes the 
transcription of proinflammatory interleukins on one sense and IRF3 and IRF7 genes 
transcription, on the other. Subsequently, the IRF3-IRF7 complex evoke the expression of 
type I IFN, which directly binds to its receptor, IFNAR, triggering the JAK/STAT pathway 
activation and caspase-11 gene transcription. Secondly, unknown scaffolding proteins 
induced by gram-negative bacteria cleave and stimulate caspase-11, which is the final 
responsible for the induction of pyroptosis and the NLRP3-ASC-caspase-1 pathway 
activation. Abbreviations: LPS- Lipopolysaccharide, TLR4- Toll like receptor 4, TRIF- Tir 
domain containing-adapter-inducing interferon beta, IRF- Interferon regulatory 
transcription factor, IFN- Interferon, IFNAR- Interferon alpha/beta receptor, JAK/STAT- 
Janus kinase/ signal transducer and activator of transcription, Gsdmd- Gasdermin D. 
	
Both canonical and non-canonical ways of NLRP3-
inflammasome activation take place independently. Nevertheless, it is 
interesting that caspase-11 has demonstrated to improve the canonical 
caspase-1 activation and IL-1b and IL-18 release in response to certain 
stimuli [165, 175]. In this context, further experiments should be 
performed to clear up the molecular mechanisms underlying the 
interaction between caspase-1 and -11 in promoting the canonical 
and/or non-canonical NLRP3 inflammasome activation. 
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5.2.3. Other NLRP3-inf lammasome activators 
Recently, several authors have reported some other proteins as 
activators of NLRP3-inflammasome as well [177-181], such as double-
stranded RNA-dependent protein kinase (PKR), guanylate-binding 
protein 5 (GBP5), and NIMA-related kinase 7 (Nek7).  
PKR has been reported to directly interact with almost all the 
known inflammasomes [178]. When PKR is removed, stimulation of 
caspase-1 and maturation of IL-1β and IL-18 is decreased in response 
to a range of stimuli. Nevertheless, additional investigations are needed 
to clarify the exact mechanism by which PKR is involved in NLRP3-
inflammasome activation. It is also believed that GBP5 has shown to 
promote the activation of NLRP3-inflammasome in response to ATP, 
nigericin and certain bacteria [177], although how the protein stimulates 
the mechanism is still unknown as well.   
Otherwise, recent data from various separate studies have 
shown the essential function of Nek7 in NLRP3-inflammasome 
activation [179-181]. Nek7 is part of the NIMA (never in mitosis gene a)-
associated expressed kinase family, which regulates the mitotic 
development and DNA damage response [182] and seems to play a 
vital role in development and survival: a study performed in mice lacking 
Nek7 showed mortality either in late embryogenesis or in early post-
natal period and severe growth delay [183]. Moreover, it has also been 
demonstrated that Nek7 is necessary for NLRP3-inflammasome 
activation by certain DAMPs including ATP, nigericin, monosodium 
urate (MSU) cholesterol crystals and alum [179, 180]. The interaction 
between Nek7 and NLRP3 is through the catalytic domain of Nek7 and 
the leucin-rich repeat (LRR) domain of NLRP3. Nek7 has recently 
shown to develop key roles in the regulation of NLRP3-inflammasome, 
including inflammasome oligomerization, ASC speck formation, and	
caspase-1 activation downstream of potassium efflux [180]. Nek7 is 
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necessary for NLRP3 activation in macrophages holding the NLRP3-
activating mutation (NLRP3 R258W) [180]. Therefore, Nek7 has an 
essential role in NLRP3 activation. Three different in vivo models have 
confirmed that lacking Nek7 leads to reduced IL-1β release, lowered 
recruitment of immune cells, and reduced illness severity in contrast to 
wild-type mice [179, 180]. Consequently, these results reveal that Nek7 
may be a positive regulator of NLRP3 inflammasome activation. 
High concentrations of extracellular K+ inhibit the interplay 
between Nek7 and NLRP3. Continual efflux is therefore required to 
maintain this interaction. Decreased intracellular K+ is prone to generate 
structural changes in NLRP3 favoring the interaction Nek7/NLRP3. 
Additionally, it also has been reported that Nek7 is still required for 
inflammasome activation even if a mutation in NLRP3 that allows K+ 
efflux exists. Conclusively, although Nek7 is therefore independently 
needed for NLRP3 inflammasome activation, a deep comprehension of 
Nek7 signaling mechanism will contribute to better understanding on 
how the mechanism of NLRP3-inflammasome activation works [180]. 
 
5.3. NLRP3-inf lammasome inhibitors 
Inflammasome’s deregulation is tightly linked to many 
autoinflammatory and autoimmune diseases, including metabolic 
disorders, such as type 2 diabetes mellitus, obesity and atherosclerosis 
as well as neurodegenerative disorders (Alzheimer’s disease, Parkinson 
disease, multiple sclerosis). The current understanding of 
inflammasome activation and its connection to inflammatory pathologies 
have therefore, drawn scientific community’s attention to develop 
potential therapies targeting inflammasomes [184].  
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Based on several preliminary data, the inhibition of NLRP3-
inflammasome is maybe one of the most interesting strategies against 
autoinflammatory and autoimmune diseases. It has been reported that 
silencing NLRP3 suppresses atherosclerosis and stabilizes plaques in 
ApoE- deficient mice [185]. The inflammasome inhibitor Arglabin, has 
shown to reduce atherosclerosis and inflammatory events in ApoE-
deficient mice [186]. Coll et al., have recently identified the attractive 
molecule MCC950, a potent and specific inhibitor of the NLRP3-
inflammasome [187]. This molecule was found to halt experimental 
NLRP3-inflammasome- associated diseases as well as inflammasome 
ex vivo control in human peripheral blood mononuclear cells (PBMCs) 
from cryopiryn-associated periodic síndrome (CAPs) patients [187].  
	
Our group has recently investigated the effect of MCC950 on 
mice fed with different kinds of diet: high-fat diet, high-sugar diet and a 
combination of both. We observed a very remarkable cardio-protective 
effect in the absence of NLRP3-inflammasome, either by genetic 
deletion or by pharmacological inhibition with MCC950 treatment [146].  
 
Hence, a close interplay between inflammation and age-related 
cardio-metabolic disorders exist. There are too many data showing that 
NLRP3 has a key role in the onset and development of age-related 
metabolic disorders, which means that new reseach might be perform in 
this field to clarify the mechanisms by which the NLRP3-inflammasome 
is involved in cardio-metabolic events related to aging and how could 
this affect to life and especially, to healthspan.  
 
In the present Thesis, we will evaluate the involvement of 
NLRP3-inflammasome in healthspan by studying cardiac and liver 
function during the aging process. 
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HYPOTHESIS AND THESIS OUTLINE 
 
We hypothesize that the deletion of NLRP3-inflammasome 
either genetically, or pharmacologically, might enhance age-related 
cardio-metabolic complications.  
 
In this Thesis, various approaches are used to evaluate the 
effect of NLRP3 gene in physiological aging (overal l  purpose). 
 
From this main purpose, arise two other specific aims:  
 
1. To dilucidate the influence of the presence or the 
absence of NLRP3-inflammasome on the regular 
biochemistry of the heart as we age (chapter 02). 
 
2. To investigate the pharmacological inhibition of NLRP3-
inflammasome by the specific molecule MCC950 
(chapter 03).  
 
Finally, chapter 04 discusses the most important findings of 
this Thesis and puts them into a broader outlook of the curret status of 
the field and the future perspectives.  
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ABSTRACT 
	
The NLRP3-inflammasome has arisen as a key element of 
inflammatory events that typically occur during aging, being responsible 
for several age-associated metabolic disorders. 
 
Based on previous data, NLRP3 knockout mice seem to be 
protected from various aspects of aging decline, but innate immune 
genetic knockouts may possess aberrant biology. In this study, we 
investigated the molecular mechanisms by which pharmacological 
inhibition of NLRP3-inflammasome may improve metabolic changes as 
we age. NLRP3 inhibition by the selective molecule MCC950 over 12 
weeks in C57BL6/J old mice resulted in enhanced metabolic function, 
mTOR pathway attenuation and subsequent improved healthspan. 
These findings suggest that the NLRP3-inflammasome inhibitor 
MCC950 might therefore, be a promising molecule for the treatment of 
metabolic diseases with a significant impact on healthspan, 
demonstrating for the first time, the potential of MCC950 molecule as 
part of an anti-aging approach. 
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INTRODUCTION 
	 	
The liver is a human organ able of innate regeneration of lost 
tissue. Nevertheless, as we age liver functionality and structure, get 
compromised, what predisposes to metabolic risk. The leading hepatic 
impairment affecting one-third of the global population is non-alcoholic 
fatty liver disease (NAFLD) and a common reason of liver transplant [1], 
easily recognizable by a typical intrahepatic accumulation of lipids.  In 
an environment of oxidative stress and inflammation, NAFLD is prone to 
evolve into non-alcoholic steatohepatitis (NASH), which constitutes a 
serious risk factor for the development of cirrhosis and hepatocellular 
carcinoma [Figure 1]. 
	
Recent research based on animal [2, 3] and human data [4] 
have connected NASH pathogenesis with peroxisome proliferator-
activated receptors (PPARs). PPARs belong to subfamily 1 of the 
nuclear receptor superfamily [5, 6], which consist of 3 different isotypes: 
α, β/δ and γ. Generally, PPARs form heterodimers with retinoid X 
receptors, enabling the transcription of diverse target genes. PPARα, in 
particular, is expressed in metabolically active tissues, and constitutes a 
major regulator of lipid metabolism in liver [7]. It regulates genes 
involved in fatty acid β-oxidation, as well as gluconeogenesis and 
inflammation. 
	
Many data based on animal models and more recently, human 
data have reported the crucial role of PPARα on the regulation of 
NASH, visceral adiposity and insulin resistance as well as its positive 
correlation with adiponectin, suggesting that PPARα might be an 
interesting therapeutic target for NASH treatment [4].  
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Figure 1. Schematic image representation of different hepatic scenarios. 
Progression of liver disease as we age and the respective molecular and lifestyle changes 
influencing hepatic state T2DM, type 2 diabetes dellitus, IR, insulin resistance, MetS, 
metabolic syndorme. Image credit modified from: 
https://www.matinasbiopharma.com/business-development/mat8800-for-treatment-of-
fatty-liver-disease 
 
On the other hand, chronic inflammation and aging,  are also 
main responsables for liver disability. As first describe Franceschi et al., 
in 2002 [8], the inflammaging theory arised as a result of a lack of 
immune system response caused by an imbalance between 
incremented inflammatory markers and decreased antioxidant enzymes 
that lies in the characteristic chronic low-grade inflammation developed 
during the aging process.  
	
As stated in this theory, the persistence of an inflammatory 
response over years symbolizes the resulting biological susceptibility to 
age-related diseases [Figure 1]. Preventing, as far as possible, chronic 
Smok ing , wes te rn - t ype d ie t , 
sedentary l i festyle, metabol ic 
disorders (Obesity, T2DM, IR, MetS)
C h r o n i c i n fl a m m a t i o n : 
Inflammatory cytokines, 
ROS, apoptosis, fibrosis…
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low-grade inflammation in aged people with a suitable lifestyle, based 
on regular physical activity and reduced caloric intake, for example, may 
be essential to promote healthspan.  
	
NLRP3-inflammasome and its association with inflammatory 
diseases, constitutes a great candidate to target hepatic inflammation 
and the metabolic events that may trigger during aging. An appealing 
inhibitor of NLRP3-inflammasome is MCC950.  
	
MCC950 is a small and selective molecule inhibitor of the 
canonical and non-canonical NLRP3-inflammasome activation [9]. 
MCC950 blocks IL-1β secretion and ASC oligomerization induced by 
active NLRP3 in mouse and human macrophages. It also decreases IL-
1β and IL-18 release, which mitigates the severity of CAPS in mouse 
models. Furthermore, what is also very interesting is that MCC950 
action is specifically on NLRP3, since it does not inhibit NLRP1, AIM2, 
NLRC4-inflammasomes activation [9]. 
	
Structurally, MCC950 consists of a dyarylsulfonilurea-derived 
compound [Figure 2]. Sulfonylureas are widely used as antidiabetic 
treatment and their main pharmacological effect is to rise in plasma 
insulin concentrations. This fact occurs for two reasons: because there 
is stimulation of insulin secretion by pancreatic β-cells, and in the 
second place, because there is a decrease in hepatic insulin clearance, 
what makes MCC950 molecule highly attractive to target age-realted 
hepatic dysfunctionality. 
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Figure 2. MCC950 molecule. Chemical structure of MCC950 molecule. Coloured box 
indicates sulfonylurea group. 
	
Some studies have reported the interest of MCC950 on NASH 
pathology, since it showed improved NAFLD and liver fibrosis in obese 
diabetic mice when NLRP3-inflammasome was inhibited [10].  
	
Further studies to test MCC950 molecule have been performed. 
After evaluating the influence of NLRP3 on heart tissue from mice, they 
concluded that pharmacological inhibition of NLRP3-inflammasome 
enhanced metabolic and inflammatory events in animal hearts as well 
as in vitro [11]. 
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MATERIALS AND METHODS 
 
Mice and animal care 
	
Animal studies were performed in accordance with the 
European Union guidelines (2010/63/EU) and the corresponding 
Spanish regulations for the use of laboratory animals in chronic 
experiments (RD 53/2013 on the care of experimental animals). All 
experiments were approved by the local institutional animal care 
committee.  
	
For all experiments, male C57/BL6/J mice were used, weighing 
30-35 g and maintained on a regular 12 h light/dark cycle. Animals were 
randomized into two different groups and at 16 weeks of age, MCC950 
treatment started. Daily doses of 20 mg/kg (drug/kg body weight) were 
administred intraperitoneally (i.p). All groups had ad libitum access to 
regular chow and water throughout the study. Regular chow or 14% 
protein rodent maintenance diet, (carbohydrate:protein:fat ratio of 
48:14:4 percent of kcal), was acquired from Teklad Global Laboratories, 
Envigo. Body weight and food intake were monitored weekly. Animal 
rooms were maintained at 20–22°C with 30–70% of relative humidity. 
 
In vitro cel l  experiments 
	
HepG2 cells, an immortalized cell line consisting of human liver 
carcinoma cells, were cultured at 37°C in a 5% CO2 atmosphere in 
DMEM medium supplemented with an antibiotic/antimycotic solution 
(Sigma Chemical Co., St. Louis, MO, USA), and 10% fetal bovine 
serum. HepG2 cells were incubated for 24 h with media containing 0.6, 
1.2 and 2.4 µM MCC950 corresponding doses.  
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Reagents 
	
MCC950 was provided by Robertson AAB and Cooper MA [9], 
from the Institute for Molecular Bioscience, (University of Queensland, 
Brisbane, Australia). Cocktail of protease inhibitors for protein 
homogenization (Complete™ Protease Inhibitor Cocktail) was 
purchased from Boehringer Mannheim (Indianapolis, IN). Bradford	
reagent for protein concentration assay was purchased from Bio-Rad 
(Madrid, Spain). 
	
Oral Glucose Tolerance Test (GTT) 
 
For oral GTT, mice were orally given glucose at 2 g/kg 
bodyweight after overnight fasting. Glucose levels in tail blood were 
measured using a glucometer (Breeze 2, Bayer Health Care, USA) at 0, 
15, 30, 60, and 120 minutes time points. 
	
Insul in Growth Factor 1 (IGF-1) 
 
Serum levels of insulin growth factor 1 (IGF-1) were assayed 
using commercial ELISA kits (R&D Systems, Minneapolis, USA). 
 
Glucose serum levels  
 
Serum levels of glucose were assayed using commercial kits 
(Randox Laboratories, Antrim, UK). 
	
Leptin and adiponectin 
 
Serum levels of leptin and adiponectin were assayed using 
commercial ELISA kits (R&D Systems, Minneapolis, USA). 
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Histology 
 
After anesthesia of mice, livers were excised and immediately 
placed in a 10% neutral-buffered formalin at room temperature for 24 
hours after a brief rinse with PBS. The specimens were embedded in 
paraffin, cut in 5-μm sections, and stained with hematoxylin and eosin. 
Liver cross-sectional areas were calculated on a digital microscope 
(×400) with ImageJ (version 1.34S) software. Masson’s trichrome 
staining was used to detect fibrosis in liver sections and fibrotic areas 
were also calculated on a digital microscope (×400) with ImageJ 
(version 1.34S) software. 
	
Western Blot Analysis 
	
Mice livers were collected and immediately snap frozen and 
homogenized for western blot analysis. Protein concentration was 
measured using a protein assay reagent (Bio-Rad, Madrid, Spain) 
according to the Bradford’s method. The immunoblot analysis was 
performed using 20 μg of total protein, separated on SDS PAGE 12% 
acrilamide gels (Biorad Laboratories Inc., Hercules, CA, USA) and 
transferred onto a nitrocellulose 0.2 µm membrane. Membrane was 
blocked in blottinng-grade blocker buffer (Biorad Laboratories Inc., 
Hercules, CA, USA) for 2 hours. After washing, the immunoblotting was 
performed at 4°C overnight with shaking using primary antibodies 
(1:1000) against Sirt1, AKT, pAKT, Beclin1, LC3, Parkin, Bcl2, BAX, 
Caspase-3, PPARα, and GAPDH (Santa Cruz Biotechnology, USA), 
AMPK, p-AMPK, PI3K, p-PI3K, mTOR, p-mTOR, SQSTM1/p62 (Cell 
Signaling, USA). After rinsing, the membranes were incubated in a 
1 : 10000 dilution with the corresponding secondary antibody coupled to 
horseradish peroxidase-conjugated (HPR) at room temperature for 
1 hour. Goat anti-rabbit IgG, goat anti-mouse and rabbit anti-goat were 
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acquired from Calbiochem-Merck Ltd (Nottingham, UK). To prove equal 
loading, the blots were analyzed for GAPDH expression using an anti-
GAPDH antibody ((Santa Cruz Biotechnology). Immunodetection was 
performed using WesternSure chemiluminescent light-detecting kit (LI-
COR Biosciencies, USA). The immunosignals were capture using C-
Digit blot scanner and image studio Digits software (LI-COR 
Biosciencies, USA). Densitometric data were recorded following 
normalization to the loading control. The signals were analyzed and 
quantified by an Image Processing and Analisys System in Java (Image 
J Software, Softonic). 
 
Microarray Analysis 
	
After twelve week-treatment, the liver from vehicle (22 months, 
n=3) and MCC950-treated (22 months, n=3) WT male mice were used 
to extract total RNA (RNeasy, QIAGEN, Valencia, CA). Quality of total 
RNA for array analysis was ascertained using an Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Biological replicates were 
synthetized, amplified, purified and the corresponding ss-DNA was 
labelled with biotin according to the manufacturer’s protocol (Affymetrix). 
100 ng of total RNA was hybridized to 5.2 μg of labelled cDNA. Then, 
hybridation, rinsing and scanning of the signal (Scanner 3000 7G, 
Affymetrix) were performed. Array data were processed using 
Affymetrix® Genechip® Command Console® 2.0 with respect to 
background subtraction and normalization. We used the Affymetrix 
ClariomTM D assay mouse, which includes 65956 genes. The raw data 
were analysed by the Affymetrix software Trancriptome Analysis 
Console. Expression values were normalized by SST (Signal Space 
Transformation)-RMA (Robust Microarray Analysis; Irizarry et al. 2003), 
and the treatment was compared versus control, using the 3 replicates 
for every analysis. Then, a fold change and p-value was calculated for 
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every gene by a unpaired test one-way (single factor) using the NMATH 
package. A gene was considered as differentially expressed when it 
had a fold change equal or higher than 1.5, and a p-value equal or lower 
than 0.05. Then, a functional enrichment was performed with the 
differentially expressed genes using the functional annotation tool from 
the DAVID web site 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381967/). So, we 
found a number of annotation categories. To analyse the expression 
profile for the genes included in these categories, a heatmap was 
created for every annotation category, using the heatmap.2 function in 
the gplots R package, and considering normalized values by z-scores, 
and making a clustering based on the expression profiles and the	
average method. Finally, a mean of the expression values in every 
annotation category was calculated and it was again plotted in a 
heatmap. 
 
Statist ical Analysis 
	
All values are expressed as arithmetic means ± SEM. Data 
were evaluated using Prism software version 6.0c (GraphPad, San 
Diego, CA). Statistical differences among the different groups were 
measured using either an unpaired Student t test or 1-way analysis of 
variance (ANOVA) when appropriate with Tukeys post-hoc test. A P 
value of ≤0.05 was considered statistically significant. Asterisks in the 
figures represent the following: *: P ≤0.05; **: P ≤ 0.01; and ***: P ≤ 0.001. 
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RESULTS 
	
Pharmacological inhibit ion of NLRP3-inf lammasome 
prevents from metabolic disorder development in aged WT 
mice 
	
To test whether pharmacological inhibition of NLRP3-
inflammasome could prevent from metabolic events onset, we 
performed a short-term assay using daily administration of the specific 
inhibitor of NLRP3, MCC950 [9]. 16-month-old male mice fed with 
standard diet (SD) and ad libitum conditions of food and drink access 
were used for these assays.  
 
Dynamic changes in body weight and food intake were 
monitored weekly during 12 weeks. Significant progressive decrease in 
body weight was observed shortly after exposing mice to MCC950-
treatment [Figure 1A]. Although food consumption seemed to remain 
unsignificant in both groups [Figure 1B], absolute food intake 
signifincantly decreased in MCC950-treated group, whereas relative 
food intake continued unarltered during the entire observation period 
[Figure 1C].  
 
We also examined the effect of MCC950 on glycemia in 
overnight fasted WT aged mice where MCC950 seemed to regulate 
serum glucose levels. A reduced AUC in this group was also observed 
[Figure 1D]. Consistent with this, basal levels of glucose and insulin-
like growth factor-1 (IGF-1) in serum were decreased in MCC950-
treated animals [Figure 1E].  
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Additional parameters, such as leptin and adiponectin serum 
levels were assayed. Adiponectin has lately drawn considerable 
attention due to its potential anti-diabetic effects. This hormone is able 
to control glucose and lipid homeostasis within the liver. It has also 
been reported that circulating adiponectin reduced plasma glucose 
levels in WT mice [12]. With this in mind, significant lower serum leptin 
levels and leptin/adiponectin ratio were detected in MCC950-treated old 
mice compared to old vehicle [Figure 1F], which is consistent with the 
metabolic parameters abovementioned. Plasma lipid levels were 
reduced in MCC950-treated mice accompanied by a significant 
reduction in hepatic transaminases, creatine phosphokinase and lactate 
dehydrogenase, among other serum biomarkers [Supplemental 
table 1]. 
 
In summary, the global beneficial metabolic effects of MCC950 
have been attributed to an improvement in serum glucose levels and 
insulin resistance, as well as a correct balance between leptin and 
adiponectin adipokines which, somehow contributes to improve 
healthspan in old mice. 
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Figure 1. Metabolic effects of NLRP3-inflammasome inhibit ion in vivo. 	
(A) Body weight curves during 12 week of MCC950 (20mg/kg) intraperitoneal (i.p) 
administration. (B) Food intake curves during 12 week-treatment with MCC950 i.p (C) 
Absolute (left) and relative (right) food intake during treatment of old WT mice. Intake was 
measured weekly during the entire treatment period. (D) Glucose serum levels at the 
indicated times after MCC950 20 mg/kg i.p administration by injection and the total area 
under the curve (AUC) for GTT in WT vehicle and MCC950-treated mice. Mice were orally 
given glucose at 2 g/kg after overnight fasting. (E) Left panel, glucose serum levels of ad 
libitum-fed mice. Right panel, insulin-like growth factor-1 serum levels of ad libitum-fed 
mice. (F) Ad libitum leptin (left), adiponectin (middle), and leptin/adiponectin ratio serum 
levels (right) at the end of the treatment. All mice were 22 months old (WT males n= 5 per 
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group) when the experiments were performed. Values are expressed as means ± SEM of 
independent experiments in triplicate .*P<0.05, **P<0.005, ***P<0.001 MCC950 vs 
vehicle. 
 
MCC950 treatment signif icantly dampened fat accumulation 
in l iver and l iver injury 
	
The pathological alterations of MCC950-treated old WT and 
vehicle WT mice after 12 weeks of treatment were firstly evaluated by 
morphologic and histological (H&E and Masson trichrome staining) 
examination. Short-term MCC950 treatment significantly enhanced liver 
fat accumulation and moderate liver steatosis [Figure 2A]. Further 
examination with Masson trichrome staining revealed hepatic fibrotic 
fibers in vehicle old mice that were absent in MCC950- treated mice 
[Figure 2B]. Some observational differences could be detected 
between the two groups. Tissue colour seemed healthier and less pale 
in MCC950-treated in comparison to the vehicle group. Moreover, 
vehicle group showed greater empirical tumour incidence [Figure 2C] 
and increased liver relative weight  [Figure 2D]. The hepatic lipid 
content test revealed that MCC950 significantly improved liver fat 
accumulation and a tendency towards reduced levels of total cholesterol 
[Figure 2E] and triglyceride [Figures 2F] in liver tissue.  
 
In summary, short-term MCC950 treatment may result in a 
progressive loss of adiposity during aging and could presumably act as 
an antitumor agent.  
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Figure 2. Effect of pharmacological inhibit ion of NLRP3-inflammasome on 
l iver fat accumulation, hepatic cholesterol and tr iglycerides. The representative 
images are represented as follow: (A) H&E staining micrographs of the liver section (400x) 
after 12-week treatment period, (B) Masson trichrome micrograph of the liver section 
(200x) after 12-week treatment period. Black arrows show collagen fibrotic fibers, (C) liver 
morphological photographs after 12-week treatment period and observational tumour 
incidence, (D) Relative weight of the liver normalized to body weight of ad libitum-fed 
mice, (E) Ad libitum liver cholesterol levels at the end of the treatment and, (F) ad libitum 
liver triglyceride content at the end of the treatment. Values are expressed as means ± 
SEM of independent experiments in triplicate (n= 5 mice for all groups). *P<0.05, 
**P<0.005, ***P<0.001 MCC950 vs vehicle. 
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MCC950 treatment may improve longevity network regulat ion 
in l iver  
 
SIRT-1, AMPK, and TOR are known to be involved in longevity 
network and lifespan. Sirt-1 is implicated in stress resistance, 
mitochondrial function, autophagy, and other actions that promote 
longevity. It has been recently reported that hepatic overexpression of 
Sirt-1 ameliorates insulin resistance in a mouse model [13], however the 
exact mechanism by which Sirt-1 cope with certain metabolic processes 
as we age remain uncertain and we observed no significant changes in 
protein expression levels [Figure 3]. AMPK modulates some important 
pathways by controlling IGF-1 and constitutes a master governor of 
metabolism, stress resistance, mitochondrial function and autophagy. 
Moreover, when AMPK is phosphorylated in a situation of nutrient 
limiting conditions, mTOR becomes inhibited and viceversa. It has been 
reported in several studies that low levels of mTOR are linked to 
lifespan and healthspan both in invertebrates and mammals [14-16]. 
Consistent with this, upregulators of mTOR pathway, PI3K and AKT, 
showed significant lower expression levels when active in liver tissue 
under MCC950 treatment [Figure 3], promoting better liver autophagy 
as well as controlled protein synthesis and stress resistance. In vitro 
experiments were performed in Thp1 cells, were NLRP3 and mTOR 
seemed to modulate each other [Supplemental f igure S1]. 
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Figure 3. MCC950 controls genes involved in longevity network. Following 
NLRP3 pharmacological inhibition with MCC950 (20mg/Kg d-1 i.p) for 12 weeks, the 
expression levels of mTOR and p-mTOR were analyzed by Western blotting. The 
corresponding expression levels of upstream effectors, AMPK, p-AMPK, AKT, p-AKT, 
PI3K and p-PI3K were also detected, as well as Sirt1. (A) Representative Western blot 
images of Sirt1, AMPK, p-AMPK, PI3K, p-PI3K, mTOR, p-mTOR, AKT, p-AKT and 
Ponceau S (loading control), (B) Densitometric quantification of protein expression levels 
of Sirt1, AMPK and p-AMPK normalized to Ponceau S and represented as relative 
expression levels, (C-E) Densitometric quantification of protein expression levels of p-
PI3K, p-mTOR, p-AKT normalized to Ponceau S and represented as relative expression 
levels. Values are expressed as means ± SEM of independent experiments in triplicate 
(n= 5 mice for all groups). *P<0.05, **P<0.005, *** P<0.001 MCC950 vs vehicle. TP: total 
protein.	
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NLRP3-inf lammasome inhibit ion enhances autophagic 
machinery  
	
The effects of MCC950 on the autophagic flux were 
investigated in 20-month old WT mice after 12 weeks of treatment. We 
apparently observed a better autophagic flux in MCC950-treated group, 
determined by the expression of LC3 II and significant decreased 
expression of proteins involved in clearance pathways such as 
SQSTM1/p62 [Figures 4A and 4B]. MCC950 also induced higher 
expression levels of important autophagic proteins, such as Beclin-1 
and lower expression of the marker protein parkin, compared with the 
counterpart vehicle group, although no significant changes were 
detected [Figures 4A and 4B]. Taking into account that LC3 II 
overexpression may have a dual meaning, since it can evoke either flux 
autophagy impairment or incremented autophagy, we should interpret 
LC3 II changes together with p62 results to say that MCC950 may 
contribute to a more efficient autophagic machinery. However, no 
significant changes were detected in apoptotic proteins [Figures 4C 
and 4D].  
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Figure 4. Effect of MCC950 treatment on autophagy signaling and apoptotic 
pathways. Representative Western blots and densitometric quantifications of (A) 
SQSTM1/p62, Parkin, LC3 II, LC3 I, Beclin1, (B) Representative Western blot images of 
Beclin1, LC3 I, LC3 II, Parkin, p62 and Ponceau S (loading control), (C) Densitometric 
quantifications of active caspase 3, BAX, Bcl2, (D) Representative Western blot images of 
Bcl2, BAX, procaspase-3, active caspase-3 and Ponceau S (loading control) in response 
to 12 week MCC950 i.p treatment. Equal loading of proteins is illustrated by Ponceau S 
bands. Values are expressed as means ± SEM of independent experiments in triplicate 
(n= 5 mice for all groups). **P<0.005, *** P<0.001 MCC950 vs vehicle. 
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Pharmacological inhibit ion of NLRP3-inf lammasome protects 
against age-dependent metabolic disorders in the l iver 
transcriptome  
	
To provide a complete overview, we performed gene 
expression profiling to further understand NLRP3-inflammasome in liver 
tissue from old mice. By comparing both groups, we observed some 
notable differences:  
	
Despite the fact it did not reach the stablished cutt-off for the list 
of genes involved in lipid metabolism during aging (1.5-fold change) 
[Figure 5A], PPAR family genes were really close to that limit (1.4-fold 
change) [Figure 5B] and particularly, PPARα resulted very attractive 
to us because of its involvement in fatty acid ß-oxidation and lipid 
metabolism in general. In adddition, it has been demonstrated that 
PPARα protects from steatosis and liver injury in both mice and humans 
[2-4].  
	
Interestingly, hepatic PPARα was upregulated in MCC950-
treated group, which was in concordance with our previous data, 
showing less lipid accummulation in mice treated with the inhibitor. We 
decided therefore to study PPARα preotein expression level in vivo and 
in vitro. Our data provide evidence that under MCC950 treatment,  
PPARα is upregulated in liver tissue as well as in HepG2, resulting 1.2 
µM, the optimal dose in vitro [Figures 5C and 5D]. Additional heat 
maps and de list of all the significantly modified gene sets can be found 
in [Supplemental f igures S2 and S3 and supplemental tables 
2 and 3]. A subset of expression genes was verified by polymerase 
chain reaction (qRT-PCR) [Supplemental f igure S4 and 
supplemental table 4]. 
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Figure 5. NLRP3-inflammasome regulates age-related changes in l iver 
transcriptome. (A) Gene expression profile comparing genes significantly up-(blue) or 
down-regulated (yellow) by either vehicle or MCC950-treated mice (Z-ratio), (B) 
Representative plot of down-(left) or up-regulated (right) PPAR family genes under 
MCC950 treatment, (C) Representative Western blot images of PPARα and GAPDH 
(loading control) of mice liver tissue, and the corresponding densitometric quantifications, 
(D) Representative Western blot images of PPARα and GAPDH (loading control) in vitro, 
and the corresponding densitometric quantifications. In vitro assay was performed in 
HepG2 cells and three different doses of MCC950 were assayed. (n= 3 mice per 
treatment). 
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DISCUSSION 
 
It is widely known that as we age, we are more prone to 
develop metabolic events, including increased cholesterol levels, 
glucose intolerance, insulin resistance, and certain hormone imbalance 
[17]. All these complications may lead to develop great tendency to 
metabolic disabilities that may trigger tissue degeneration. Additionally, 
the typical age-related systemic and chronic inflammatory state 
improves the chances of insulin resistance onset in muscle and adipose 
tissue, driving to energy homeostasis imbalance and disturbed cellular 
functions. 
 
In concordance with the inflammaging theory, it has been 
reported that reduction of NLRP3-inflammasome dependent 
proinflammatory cascade, mitigated age-associated deteriorating 
changes in most organs [18].  
 
In this scenario, research on NLRP3-inflammasome inhibitors 
has become very attractive. Our findings provide data of how the 
specific inhibitor MCC950 may be a key component in the prevention of 
age-related metabolic disorders and subsequent extended healthspan.  
 
Although similar feeding conditions were performed, MCC950 
treated mice showed less body weight gain. After short-term MCC950 
treatment, metabolic profile was improved, showing better glucose 
response and higher levels of circulating adiponectin, which is directly 
correlated with improved insulin sensitibity [19]. Lower serum levels of 
leptin were also observed in MCC950-treated mice, what reflects 
smaller adipose tissue size and suggests that its secretion might be 
regulated by the NLRP3-inflammasome dependent proinflammatory 
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cytokines [20, 21], as well as a suitable ratio leptin: adiponectin. 
According to this, lipid accumulation in liver tissue was reduced after 
pharmacological inhibition of NLRP3, as well as fibrotic fibers. Liver 
size, total cholesterol and triglyceride levels resulted significantly 
diminished. All these observations on the protective effect of MCC950 
against liver injury onset in aged mice are in concordance with a novel 
study performed in obese mice where this molecule enhanced NAFLD 
pathology [10]. Moreover, microarray data showed interesting data of 
upregulated genes improving lipid metabolism and inflammation [7] 
which supports the abovementioned results. Taken these data together, 
MCC950 effects might be due to the blockade of cholesterol crystals 
activating NLRP3-inflammasome in myeloid cells.  
 
There is abundance evidence on mainly four model organisms 
sharing conserved genes that establish complex interrelationships 
among them involved in aging and lifespan. From yeast to mammals, all 
of the aforementioned organisms showed extended lifespan when 
mTOR and mTOR upregulators were attenuated and AMPK, however 
remained active [22-27], which apart from contributing to extend 
lifespan and healthy aging, its chronic activation has shown to decrease 
adiposity in liver tissue [27]. Taking this into account, NLRP3-
inflammasome showed to be involved in longevity network regulation, 
since after using the inhibitor, the expression of several genes playing 
crucial roles in life and healthspan, including mTOR, PI3K, AKT, were 
significantly decreased, whereas AMPK was overexpressed in the livers 
of MCC950-treated group. These experiments were reproduced in vitro, 
where we observed that NLRP3 could somehow regulate mTOR 
pathway and viceversa, resulting in healthier aging promotion. 
 
Autophagy is a main cytoprotective mechanism contributing to 
cellular homeostasis whose dysfunction is associated with a variety of 
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pathologies including heart and liver disease. As we age, authophagic 
machinery becomes impaired and less effective, causing defective 
clearance and therefore, contributing to tissue damage [28]. Autophagy 
and autophagy-related proteins are vital to modulate inflammatory 
response, since autophagy is connected to innate immune receptors 
ensuring the intracellular degradation of microbial presence or ROS. 
Besides, the activation of autophagy by inflammatory signals limits 
proinflammatory cytokines production by targeting inflammasomes to 
ensure their elimination [29]. According to this, our results indicate that 
MCC950 inflammasome inhibitor, contributes to ameliorate autophagic 
flux. 
 
Notably, enhanced healthspan in mice treated with MCC950 is 
associated with amelioration of lipid and glucose metabolism, 
autophagy and the regulation of genes involved in longevity pathways. 
Moreover, MCC950 seemed to upregulate PPARα, which contributes to 
the abovementioned improved metabolic profile. Although more 
research should be performed in this field to provide more data of how 
MCC950 could affect other tissues, our data demonstrate that 
pharmacological inhibition of NLRP3-inflammasome extends healthspan 
by preventing old mice from aged-related metabolic disabilities, 
including better glucose assimilation, less insulin resistance as well as 
ameliorated autophagic flux and the regulation of important genes 
involved in longevity pathways. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, our data suggests that MCC950 molecule shows 
beneficial metabolic and inflammatory effects, as well as ameliorated 
autophagic machinery in aged mice liver tissues.  
Pharmacological inhibition of NLRP3-inflammasome may hold a 
promising therapy to extend healthspan by enhancing age-related 
metabolic disabilities. Based on our findings, future studies will be 
required to test the hypothesis that the inhibition of NLRP3-
inflammasome with the specific molecule MCC950 extends healthspan 
in aged individuals. 
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SUPPLEMENTAL MATERIAL 
	
Supplementary methods 
 
Thp1 experiments 
 
THP-1 cells, a human leukemia monocytic cell line extensively 
used to study monocyte/macrophage functions, were cultured at 37°C in 
a 5% CO2 atmosphere in RPMI-1640 medium supplemented with L-
glutamine, an antibiotic/antimycotic solution (Sigma Chemical Co., St. 
Louis, MO, USA), and 10% fetal bovine serum.  
To induce NLRP3-activation, cells were expose to LPS (250 
ng/ml, 4h) for priming, and to ATP (5mM, 24h) for triggering. For protein 
synthesis experiment, cells were treated with puromycin (1µM) and 
harvested after 30 minutes. 
 
Serum biomarkers 
	
Serum levels of cholesterol, triglycerides, albumin, bilirubin, 
alanine and aspartate aminotransferases, lactate dehydrogenase, 
creatine phosphokinase, uric acid and creatinine were assayed using 
commercial kits (Randox Laboratories, Antrim, UK). 
 
	
QRT-PCR analysis 
	
Total RNA from mouse liver was extracted using RNeasy 
Tissue Mini Kit (QIAGEN) and treated with DNase. CDNA was 
synthesized using iScript (BioRad) cDNA kit. QRT-PCR was performed 
on the ROCHE LightCycler® 96 Instrument with SYBR Green Master 
Mix (BioRad) using 50 ng of cDNA per reaction with 3x 
reactions/sample. ß-actin was used as housekeeping gene. All primers 
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were designed based on Primer 3plus and can be found in 
Supplementary Table 4.  
	
Protein synthesis 
 
Briefly, the cells were incubated with serum-free DMEM for 90 
min followed by incubation with 1 µM puromycin (an analogue of tyrosyl-
tRNA; Invitrogen; A11138-03) for 30 min. The amount of puromycin 
incorporated into nascent peptides was then evaluated by Western blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Inhibit ion of the NLRP3-inflammasome by MCC950 improves healthspan 
in aged mice 	
	144	
Supplemental f igures  
 
 
Supplemental f igure 1. NLRP3-inflammasome might be involved in 
autophagy and protein synthesis by regulating TOR pathway and viceversa. 
(A) Western Blot images showing NLRP3 and TOR pathway, using NLRP3 activators, 
such as LPS and ATP and NLRP3 and mTOR inhibitors, MCC950 and rapamycin, 
respectively. (B) Western Blot analaysis showing autophagy markers: LC3, p62, Beclin1, 
pAKT, AKT, (C) Protein synthesis was quantified in protein extracts treated with MCC950 
using puromycin labeling followed by immunoloblot. NT: No treatment. 
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Supplemental f igure 2. Inhibit ion of NLRP3 protects age-related l iver 
disorders in transcriptome. (A) Principal component analysis (PCA) was performed in 
differentially expressed genes from the liver of mice treated with the vehicle or MCC950. 
Each data point corresponds to the PCA analysis of each subject, (B) Volcano plots of 
gene expression difference in liver in vehicle and MCC950-treated old mice. Grey color 
means gene probes that do not reach cuto-ff levels for statistical significance as well as 
fold change. Green color represents genes with decreased expression in aged MCC950-
treated mice when compared to aged vehicle; whilst, red color marks genes with 
increased expression in MCC950-treated mice, (C) Representation of the 479 genes that 
reached the cut-off, of which, 65% were upregulated and 10% were downregulated on 
liver tissue from vechicle and MCC950-traeted mice.  
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Supplemental f igure 3. Microarray data. Effect of MCC950 on phosphorylation, 
oxidation-reduction processes, regulation of cell growth and lysosomal and endosomal 
regulation during aging.  
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Supplemental f igure 4. qRT-PCR Validation. qRT-PCR Validation of various up- 
and down-regulated genes from microarray analaysis.	
	
	
Supplemental tables 
 
Supplemental table 1. Effects of MCC950 treatment on various serum biomarkers. 
	
Parameters Old vehicle       Old MCC950 
Cholesterol (mg/dL) 310.9 (15.2) 190.1 (17.4)*** 
Triglycerides (mg/dL) 73.81 (13.4) 69.15 (16.1) 
Albumin (mg/dL) 2.31 (0.12) 2.02 (0.11) 
Bilirubin (mg/dL) 0.16 (0.01) 0.14 (0.02) 
Ala aminotransferase (UL) 499.8 (71) 315.37 (85)** 
Asp aminotransferase (UL) 471.8 (83) 364.8 (97)** 
Lactate dehydrogenase (UL) 1499 (198) 987 (211)*** 
Creatine phosphokinase (UL) 6190 (998) 4127 (691)*** 
Uric Acid (µMol/dL) 28.15 (4.3) 26.31 (6.1) 
Creatinine (mg/dL) 0.65 (0.05) 0.62 (0.03) 
 
Values are presented as mean ± SEM. UL, units per litre. *P˂0.05, **P˂0.005, ***P˂0.001 
versus vehicle. (n=10). 
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Supplemental table 2. Microarray data. Genes significantly upregulated after 
MCC950-treatment. (FDR<0.05, more than 1.5 fold). 
	
Gene 
Symbol 
Fold 
change 
(linear) 
ANOVA  
p-value 
FDR  
p-value 
Accession number 
Pck1  5,82 0,04182 0,97452 NM_011044 
Herpud1  5,38 0,000808 0,820725 NM_022331 
Saa4  4,12 0,000686 0,820725 NM_011316 
Arrdc3  3,84 0,044751 0,97452 NM_001042591 
Angptl4  3,51 0,025994 0,97452 NM_020581 
Egr1  3,32 0,040501 0,97452 NM_007913 
Selenbp2  3,23 0,005968 0,97452 NM_019414 
Cyp2d13  3,2 0,009951 0,97452 NR_003552 
Rgs16  2,99 0,047614 0,97452 NM_011267 
Serpina3n  2,68 0,007576 0,97452 NM_009252 
Selenbp1  2,67 0,008072 0,97452 NM_009150  
Bst2  2,35 0,005907 0,97452 NM_198095  
Sdc4  2,35 0,016673 0,97452 NM_011521  
Rplp1  2,33 0,038841 0,97452 NM_018853  
Aox3  2,31 0,045074 0,97452 NM_023617  
Fbxo21  2,28 0,022739 0,97452 NM_145564  
Nr0b2  2,25 0,029354 0,97452 NM_011850  
Slc25a47  2,21 0,024702 0,97452 NM_001012310  
Lims2  2,1 0,002503 0,97452 NM_144862  
Slc17a2  2,1 0,046818 0,97452 NM_144836  
F11  2,06 0,024048 0,97452 NM_028066  
Dbp  2,01 0,038376 0,97452 NM_016974  
Slc8b1  2 0,002515 0,97452 NM_001177594  
Ifi27  2 0,008159 0,97452 NM_026790  
Vkorc1  1,98 0,038492 0,97452 NM_178600  
Il6ra  1,93 0,003168 0,97452 NM_010559  
Erbb3  1,88 0,006558 0,97452 NM_010153  
Igfbp2  1,85 0,028556 0,97452 NM_008342  
Rps27rt  1,84 0,00542 0,97452 ENSMUST00000053150 
Sephs2  1,81 0,008951 0,97452 NM_009266  
Marf1  1,8 0,003662 0,97452 NM_001081154  
Zfp36l2  1,78 0,010715 0,97452 NM_001001806  
Erdr1  1,77 0,02906 0,97452 NM_133362  
Cep85l  1,77 0,047017 0,97452 NM_001204983  
Etnk2  1,76 0,028711 0,97452 NM_175443  
Lrp1  1,74 0,010182 0,97452 NM_008512  
Lcat  1,73 0,004131 0,97452 NM_008490  
Ighv7-3  1,73 0,005503 0,97452 ENSMUST00000103461  
Mir466f-2  1,72 0,026186 0,97452 ENSMUST00000104805  
Rps27rt  1,71 0,037421 0,97452 NM_001190258 
Mrip-ps  1,7 0,016848 0,97452 OTTMUST00000117311 
Npc1  1,69 0,005546 0,97452 NM_008720  
Vmn1r39  1,68 0,014043 0,97452 NM_001166720  
Gne  1,68 0,021982 0,97452 NM_001190414  
Avpr1a  1,67 0,02639 0,97452 NM_016847  
n-R5s153  1,64 0,022413 0,97452 ENSMUST00000083451  
Slc7a2  1,64 0,046524 0,97452 NM_001044740  
Upp2  1,63 0,0009 0,820725 NM_001289659  
Sgms2  1,63 0,00814 0,97452 NM_028943  
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Cyp2d41-ps  1,63 0,043645 0,97452 OTTMUST00000112044  
Dnajc3  1,63 0,046726 0,97452 NM_008929  
Ifit1  1,62 0,008412 0,97452 NM_008331  
Tmem50a  1,61 0,000828 0,820725 NM_027935  
Olfr846  1,61 0,048127 0,97452 NM_146282  
C6  1,6 0,038104 0,97452 NM_016704  
Mafb  1,59 0,007077 0,97452 NM_010658  
Trp53inp1  1,57 0,037755 0,97452 NM_001199105  
Masp1  1,57 0,043801 0,97452 NM_008555  
Abcg5  1,56 0,034109 0,97452 NM_031884  
Mir3966  1,55 0,026528 0,97452 NR_039547  
Rab43  1,55 0,027935 0,97452 NM_001039394  
Gys2  1,55 0,034804 0,97452 NM_145572  
Zbtb16  1,55 0,037067 0,97452 NM_001033324  
C1rb  1,55 0,040777 0,97452 NM_001113356  
F12  1,55 0,048214 0,97452 NM_021489  
Il1r1  1,54 0,014788 0,97452 NM_001123382  
Maf  1,54 0,023496 0,97452 NM_001025577  
Msrb1  1,54 0,028941 0,97452 NM_013759  
Cmtm8  1,54 0,029956 0,97452 NM_027294  
Tgtp2  1,53 0,04922 0,97452 NM_001145164  
H6pd  1,52 0,005755 0,97452 NM_173371  
Igfbp7  1,52 0,010924 0,97452 NM_001159518  
Igkv2-109  1,52 0,027246 0,97452 NCBI_Gene:628268  
Olfr821  1,52 0,038342 0,97452 NM_146776  
Scarb1  1,51 0,003537 0,97452 NM_001205082  
	
Values of fold change (linear), ANOVA p-value, and FDR p-value are represented as 
MCC950 vs vehicle. 
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Supplemental table 3. Microarray data. Genes significantly downregulated after 
MCC950-treatment. (FDR<0.05, more than 1.5 fold). 
	
Gene 
Symbol 
Fold 
change 
(linear) 
ANOVA  
p-value 
FDR  
p-value 
Accession number 
Gpam  -4,97 0,043305 0,97452 NM_008149  
Tubb2a  -2,92 0,001043 0,820725 NM_009450  
Me1  -2,9 0,024593 0,97452 NM_001198933  
Cidea  -2,78 0,002715 0,97452 NM_007702  
Cd36  -2,44 0,000698 0,820725 NM_001159555  
Lgals1  -2,43 0,028547 0,97452 NM_008495  
Mir1958  -2,15 0,047763 0,97452 NR_035484  
Mfsd2a  -2,1 0,017813 0,97452 NM_029662  
Snord90  -2,08 0,021007 0,97452 NR_028535  
Rdh16  -2 0,046762 0,97452 NM_009040  
Onecut1  -1,97 0,02037 0,97452 NM_008262  
Vmn1r204  -1,87 0,006055 0,97452 NM_001045544  
Klhl34  -1,79 0,029266 0,97452 NM_001081667  
Tcrg-V6  -1,79 0,034813 0,97452 NCBI_Gene:21640  
Olfr101  -1,78 0,001039 0,820725 NM_146834  
G6pdx  -1,75 0,017411 0,97452 NM_008062  
Ift88os  -1,73 0,020171 0,97452 ENSMUST00000149702  
Xlr3c  -1,71 0,02238 0,97452 NM_011727  
Cyp2b13  -1,71 0,035242 0,97452 NM_007813  
Tuba1c  -1,69 0,003109 0,97452 NM_009448  
Scgb2b19  -1,68 0,000418 0,820725 NM_001199336  
Acot3  -1,67 0,03839 0,97452 NM_134246  
Mir6910  -1,66 0,00532 0,97452 NR_105875  
Igkv4-61  -1,65 0,035479 0,97452 NCBI_Gene:546244  
Ap5s1  -1,64 0,044448 0,97452 NM_027129  
Hist1h4f  -1,64 0,045277 0,97452 NM_175655  
Mir6412  -1,63 0,000959 0,820725 ENSMUST00000184477  
Igkv4-58  -1,59 0,023294 0,97452 NCBI_Gene:381831  
Tubb2b  -1,57 0,010945 0,97452 NM_023716  
Igkv4-81  -1,56 0,035199 0,97452 NCBI_Gene:243453  
Vmn2r-ps19  -1,55 0,026644 0,97452 OTTMUST00000111832  
Tas2r126  -1,54 0,018614 0,97452 NM_207028  
Msl3l2  -1,53 0,023084 0,97452 NM_001163833  
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Mrap  -1,52 0,002825 0,97452 NM_029844  
Olfr734  -1,52 0,00685 0,97452 NM_146664  
Mrps23  -1,52 0,018428 0,97452 NM_024174  
Traj25  -1,52 0,038061 0,97452 NCBI_Gene:100124364  
Cs  -1,52 0,04376 0,97452 NM_026444  
Olfr779  -1,51 0,00109 0,820725 ENSMUST00000069063  
Tubb4b-ps1  -1,51 0,017976 0,97452 ENSMUST00000179460  
	
Values of fold change (linear), ANOVA p-value, and FDR p-value are represented as 
MCC950 vs vehicle. 
	
Supplemental table 4. Primer pairs used for real-time-PCR analyses for microarray 
validation.	
	
	
	
	
	
	
	
	
	
	
	
Target Accesion 
Number 
Direction Sequence (5’-3’) 
 
Pck1 NM_011044.2 
 
Forward 
Reverse 
GTCAACACCGACCTCCCTTA 
CATTGTGCCGCTATCTCAAA 
Npc1 NM_008720.2 
 
Forward 
Reverse 
ACCAGCAGTGTTGGGATAGG 
CATGTGTTGGGACTCCACAG 
Herpud1 NM_022331.1 
 
Forward 
Reverse 
ACAAAGGGTGCTGAATCCAC 
CCTTGGAAAGTCTGCTGGAC 
Cidea NM_007702.2 
 
Forward 
Reverse 
GCAGCCTGCAGGAACTTATC 
CCATTTCTGTCCCTTTTCCA 
Lrp1 NM_008512.2 
 
Forward 
Reverse 
CTGAAGGCTCCGAGTACCAG 
GTAGGAGATTGTGCCCGTGT 
ß-actin NM_007393.5 
 
Forward 
Reverse 
TGTTACCAACTGGGACGACA 
GGGGTGTTGAAGGTCTCAAA 
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GENERAL DISCUSSION  
 
Aging is the greatest risk factor for the development of cardio-
metabolic events. Genetics, inactivity, overnutritition and, in general, 
unhealthy behavioural habits are main contributors to chronic low-grade 
inflammatory state, triggering aged-related diseases [1]. 
 
Both NLRP3-inflammasome deletion and its inhibiton with 
MCC950 showed progressive decrease in body weight gain and almost 
unaltered food intake during the entire observation periods. Better 
glucose response, insulin sensitivity and adiponectin serum levels were 
dectected in the absence of the inflammasome NLRP3, what 
demonstrated an enhancement in cardio-metabolic parameters. 
Moreover, reduced levels of circulating glucose and IGF-1 have been 
reported to be indicatives of stress resistance and are linked to 
antiaging effects [2]. Adipokines such as leptin and adiponectin, and the 
leptin/adiponectin ratio, are highly linked to CVD, metabolic syndrome, 
type 2 diabetes mellitus and NAFLD [3]. Both NLRP3-inflammasome 
deletion and MCC950-treated mice showed reduced leptin and 
leptin/adiponectin ratio levels as well as an increase in circulating 
adiponectin.  
 
Furthermore, some interesting genes resulted up- or 
downregulated by performing microarray profiling in MCC950-treated 
liver tissue. Npc1, pck1, herpud1 and lpr1, which are involved in 
metabolic response, including cellular cholesterol content [4], increased 
gluconeogenesis, adequate glucose uptake [5] and hepatic insulin 
resistance [6] respectively, resulted upregulated. However, cidea was 
downregulated, which is associated with less severity of liver steatosis 
[7] and in concordance with previous metabolic results. Interestingly, 
overexpressed PPAR family genes were pretty close to the cut-off 
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stablished (1.4-fold change), what indicated once more, better lipid 
metabolism both in vivo and in vitro.  
 
Taking these data together, NLRP3-inflammasome inhibition or 
deletion has shown to enhance cardio-metabolic homeostasis during 
the aging process.  
 
It is widely acknowledged that some changes take place at 
cardiac level as we age. Even healthy aged individuals experiment heart 
weight gain and slight age-associated ECG variations. The 
accumulation of lipid content, such as lipofucsin and fibrotic tissue, are 
common aspects of the elderly as well. However, old NLRP3-/- mice 
showed less incidence of fibrosis, less LV occlusion and decreased 
heart size. All these changes were associated with animals less prone 
to atrial fibrillation and therefore, minor risk to develop heart failure [8, 
9], which may correlate with healthier aging and extended healthspan 
through cardiac function improvement. 
 
Apart from heart alterations and changes that aging triggers, 
morphological variations in liver do occur as part of physiological aging 
even in healthy individuals. Liver steatosis and fibrotic tissue as well as 
total cholesterol and TGs levels in liver resulted reduced after MCC950 
treatment. Moreover, hepatic reduction of liver weight and reduced 
visual tumor incidence inspection were associated with MCC950 
metabolic effects.  
 
The scientific community has made numerous endeavours to 
further understand how cardio-metabolic events take place and develop 
during aging. Cardiac and liver homeostasis is partly regulated by the 
kinase mTOR. The mTOR pathway has been largely studied because of 
its involvement in longevity, and given the observed low levels of IGF-1 
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in the absence of NLRP3-inflammasome in old mice, and the already 
existing evidence reporting that mTOR partial attenuation is beneficial 
for cell survival and lifespan [10], assays on mTOR pathway signalling 
were considered. It has been reported that mTOR activation is related to 
cardiac hypertrophy and genetic complications at cardiac level [11, 12].  
Interestingly, NLRP3-/- mice presented parcial inhibition of mTOR in the 
heart since early ages, what significantly protected this group from 
cardiac decline during aging.  
 
A similar situation was observed in liver. Reduced protein 
expression levels of phosphorylated PI3K, AKT and mTOR and 
increased levels of phospho-AMPK in old mice after MCC950-treatment 
were detected. AMPK and AKT are regulators of mTOR. The attenuated 
hepatic mTOR levels were therefore, due to increased expresion of p-
AMPK and reduced levels of p-AKT in liver tissue as well.  
 
Attenuated pmTOR expression in heart and liver tissue of 
NLRP3-inflammasome KO mice and MCC950-treated WT mice 
contributed to autophagic machinery activation [13, 14]. Autophagy is 
the main cytoprotective mechanism involved in cellular homeostasis 
whose impairment is highly associated with cardio-metabolic disabilities. 
It is already known, that autophagy process becomes less effective with 
aging, contributing to cardiac and liver damage [15]. Cardiac decline 
during aging triggers stress which, as a strategy of cell survival 
activates autophagy machinery. NLRP3-/- mice presented rapid 
autophagy and great autophagic flux maintained over time, which 
exerted cardioprotective effects in old NLRP3-/- group.  
 
In liver, ameliorated autophagic flux was detected as well. 
Autophagy-related proteins regulate innate immune response 
inflammatory responses by ensuring intracellular degradation of PAMPs 
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and DAMPs [16]. When inflammatory signals activate autophagy, the 
production of proinflammatory cytokines gets limited by targeting the 
inflammasomes. Besides, it has been recently reported that MCC950 
treatment in mice induced autophagy and improved autophagic flux 
after high energy-content diet [14], what is in concordance with our data 
obtained in liver tissue. In vitro experiments in Thp1 cells showed 
similar autophagic profile when treated either with MCC950 or 
rapamycin. Surprisingly, MCC950’s effect is attributable to the inhibition 
of mTOR pathway shortly after ATP and LPS treatment to activate 
NLRP3-inflammasome. Liver environment was reproduced in vitro using 
HepG2 cells treated with MCC950, which resulted in induced autophagy 
and a reduction of protein synthesis. A characteristic effect when mTOR 
is partially inhibited.  
 
Accordingly, MCC950 effects are in concordance with previous 
studies regarding NLRP3-inflammasome deletion, where animals 
exerted better glycemic control, ameliorated cognitive function as well 
as attenuated bone loss [17]. Moreover, this is also consistent with data 
obtained in chapter 02, where NLRP3 genetic ablation enhanced 
cardiac function in young and old NLRP3-/-mice. 
 
Although genetic modifications are a great strategy to target 
age-related cardiometabolic events since early ages, pharmacological 
intervention should be taken into account as an interesting approach to 
extend healthspan in humanbeing.  
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GENERAL CONCLUSIONS  
 
From this Thesis it can be cocluded that:  
 
1. NLRP3-inflammasome genetic deletion ameliorates cardio-
metabolic homeostasis by improving glucose response, insulin 
resistance, and leptin/adiponectin ratio when compared with 
WT mice of the same age.  
 
2. NLRP3-inflammasome deletion extends medium lifespan. 
 
3. NLRP3-inflammasome deletion delays cardiac aging by 
exerting cardioprotective effects.  
 
4. NLRP3-inflammasome deletion induces mTOR attenuation, 
which results in improved autophagy machinery and autophagic 
flux.  
 
5. Pharmacological specific inhibition with MCC950 reproduced 
similar effects in aged treated mice, amelioranting metabolic 
liver profile and age-related changes in liver transcriptome.  
 
6. MCC950-treated old mice presented enhanced autophagy as 
well as less expression of mTOR pathway signalling proteins. 
 
7. Both NLRP3-inflammasome genetic modification and MCC950 
pharmacological inhibition contributed to general improvement 
of cardiac and liver function in the elderly, promoting healthy 
aging and extended healthspan when compared with WT or 
vehicle-treated animals of the same age. 
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LIST OF ABBREVIATIONS 
 
AD, Alzheimer’s disease 
AMPK, AMP-activated protein kinase 
AKT, Serine/threonine kinase Akt 
ALR, AIM2-like receptor 
ASC, Apoptosis-associated speck-like containing a caspase domain 
ATP, Adenosine triphosphate 
CAPS, Cryopyrin-associated periodic fever syndromes 
CKD, Chronic kidney disease 
COPD, Chronic obstructive pulmonary disease 
COX, Cytochrome C oxidase 
CR, Calorie restriction 
CVD, Cardiovascular disease 
DAMPs, damage-associated molecular patterns 
eNOS, Endothelial nitric oxide synthetase 
ERK1/2, Extracellular signal-regulated kinase 
GBP5, Guanylate-binding protein 5 
Gsdmd, Gasdermin D 
IGF-1, Insulin/insulin-like growth factor 1 
IL, Interleukin 
IFN, Interferon 
IFNAR, Interferon alpha/beta receptor 
IRF, Interferon regulatory transcription factor 
JAK/STAT, Janus kinase/signal transducer and activator of 
transcription 
LC3, Microtubule associated protein 1 light chain 3 
LRR, Leucin-rich repeat domain 
LPS, Lipopolysaccharide 
MD, Macular degeneration 
MetS, Metabolic syndrome 
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mtDNA, Mitochondrial DNA 
mTOR, Mammalian target of rapamycin 
NAD, Nicotinamide adenine dinucleotide 
NAFLD, Non-alcoholic fatty liver disease 
Nampt, Nicotinamide phosphoribosyltransferase 
NASH, Non-alcoholic steatohepatitis 
Nek7, NIMA-related kinase 7 
NF-kß, Nuclear factor kappa beta 
NO, Nitric oxide 
NLR, Nod-like receptor 
OST, Oxidative stress theory 
PAMPs, Pathogen-associated molecular patterns 
PARP-1, Poly (ADP-ribose) polymerase-1 
PBMCs, Peripheral blood mononuclear cells 
PD, Parkinson’s disease 
PKR, RNA-dependent protein kinase 
PPARs, Peroxisome proliferator-activated receptors 
ROS, Reactive oxygen species 
SASP, Senescence-associated secretory phenotype 
TLR4, Toll-like receptor 4 
TRIF, Tir domain containing-adapter-inducing interferon beta 
T2DM, Type 2 diabetes mellitus 
ULK1, Unc-51 like kinase-1 
WHO, World Health Organization 
 
 
 
This is a list of most used abbreviations, but we have decided to 
spell out each abbreviation the first time it is used in each chapter, 
followed by the abbreviation in parentheses.  
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